• Explore /
  • Poster
  • / First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Video & Slides Poster

Authors

null

Dana E. Rathkopf

Memorial Sloan Kettering Cancer Center, New York, NY

Dana E. Rathkopf , Manish R. Patel , Atish Dipankar Choudhury , Drew W. Rasco , Nehal J. Lakhani , Jessica E. Hawley , Ana Aparicio , Vivek Narayan , Sandy Srinivas , Karie Runcie , Hamid Emamekhoo , Zachery R Reichert , Michael Anthony Carducci , Amber L. Wells , Can Liu , Raju Kandimalla , Jiaju Wu , Marie Huong Nguyen , Michael Pourdehnad , Andrew J. Armstrong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04428788

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 134)

DOI

10.1200/JCO.2024.42.4_suppl.134

Abstract #

134

Poster Bd #

F5

Abstract Disclosures

Similar Posters

First Author: Benedito A. Carneiro

First Author: Karim Fizazi

First Author: Sumit Kumar Subudhi

First Author: Alexandra Sokolova